These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 15684606)

  • 21. The Thioredoxin System: A Promising Target for Cancer Drug Development.
    Ghareeb H; Metanis N
    Chemistry; 2020 Aug; 26(45):10175-10184. PubMed ID: 32097513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the reduction-oxidation potential of the thioredoxin-like domains of protein disulfide-isomerase from the equilibrium with glutathione and thioredoxin.
    Lundström J; Holmgren A
    Biochemistry; 1993 Jul; 32(26):6649-55. PubMed ID: 8329391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Properties and biological activities of thioredoxins.
    Powis G; Montfort WR
    Annu Rev Pharmacol Toxicol; 2001; 41():261-95. PubMed ID: 11264458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Properties and biological activities of thioredoxins.
    Powis G; Montfort WR
    Annu Rev Biophys Biomol Struct; 2001; 30():421-55. PubMed ID: 11441809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
    Huang J; Xu J; Tian L; Zhong L
    Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of thioredoxin system and targeted therapies for acute leukemia.
    Xie W; Ma W; Liu P; Zhou F
    Mitochondrion; 2019 Jul; 47():38-46. PubMed ID: 31029641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two resident ER-proteins, CaBP1 and CaBP2, with thioredoxin domains, are substrates for thioredoxin reductase: comparison with protein disulfide isomerase.
    Lundström-Ljung J; Birnbach U; Rupp K; Söling HD; Holmgren A
    FEBS Lett; 1995 Jan; 357(3):305-8. PubMed ID: 7835433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems.
    Sun QA; Kirnarsky L; Sherman S; Gladyshev VN
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3673-8. PubMed ID: 11259642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of thioredoxin in lung disease.
    Xu J; Li T; Wu H; Xu T
    Pulm Pharmacol Ther; 2012 Apr; 25(2):154-62. PubMed ID: 22293327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation response of cells during altered protein thiol redox.
    Biaglow JE; Ayene IS; Koch CJ; Donahue J; Stamato TD; Mieyal JJ; Tuttle SW
    Radiat Res; 2003 Apr; 159(4):484-94. PubMed ID: 12643793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Balanced Regulation of Redox Status of Intracellular Thioredoxin Revealed by in-Cell NMR.
    Mochizuki A; Saso A; Zhao Q; Kubo S; Nishida N; Shimada I
    J Am Chem Soc; 2018 Mar; 140(10):3784-3790. PubMed ID: 29509009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. General acid/base catalysis in the active site of Escherichia coli thioredoxin.
    Chivers PT; Raines RT
    Biochemistry; 1997 Dec; 36(50):15810-6. PubMed ID: 9398311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
    Arnér ES; Nakamura H; Sasada T; Yodoi J; Holmgren A; Spyrou G
    Free Radic Biol Med; 2001 Nov; 31(10):1170-8. PubMed ID: 11705695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanistic characterization of the thioredoxin system in the removal of hydrogen peroxide.
    Pannala VR; Dash RK
    Free Radic Biol Med; 2015 Jan; 78():42-55. PubMed ID: 25451645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
    Liu Y; Li Y; Yu S; Zhao G
    Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redox active disulfides: the thioredoxin system as a drug target.
    Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
    Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.
    Pennington JD; Jacobs KM; Sun L; Bar-Sela G; Mishra M; Gius D
    Curr Pharm Des; 2007; 13(33):3368-77. PubMed ID: 18045191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential Anticancer Activity of Auranofin.
    Onodera T; Momose I; Kawada M
    Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
    Lu J; Chew EH; Holmgren A
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thioredoxin system in cell death progression.
    Lu J; Holmgren A
    Antioxid Redox Signal; 2012 Dec; 17(12):1738-47. PubMed ID: 22530689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.